XNAS
ARAY
Market cap31mUSD
Jul 09, Last price
0.26USD
1D
4.35%
1Q
-32.29%
Jan 2017
-94.26%
IPO
-99.10%
Name
Accuray Inc
Chart & Performance
P/E
—
P/S
0.07
EPS
—
Div Yield, %
—
Shrs. gr., 5y
2.55%
Rev. gr., 5y
3.67%
Revenues
459m
+2.68%
Net income
-2m
L-89.77%
CFO
3m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Accuray Incorporated, established in 1990 with its headquarters in Sunnyvale, California, specializes in the development, production, and distribution of sophisticated radiosurgery and radiation therapy systems. These advanced medical devices are designed to combat tumors and are deployed across a vast international market, spanning the Americas, Europe, the Middle East, India, Africa, Japan, China, and the wider Asia Pacific region. Among its key product lines is the CyberKnife System, an advanced robotic platform utilized for stereotactic radiosurgery and stereotactic body radiation therapy. This system is adept at treating a diverse range of malignant growths and tumors found throughout the body, including those affecting the prostate, lungs, brain, spine, liver, pancreas, and kidneys. Additionally, Accuray offers the TomoTherapy System, which incorporates the Radixact System – an integrated radiation therapy solution engineered to address a broad spectrum of cancer types. Beyond its core equipment, the company provides comprehensive support services to its clientele. These include ongoing post-purchase maintenance, system installation, operational training, and various other specialized professional services. Accuray employs a multi-pronged sales approach; within the United States, it primarily sells directly to healthcare institutions such as hospitals and independent treatment centers via its own sales force, augmented by sales agents and group purchasing organizations. Internationally, sales are conducted directly to clients, alongside a network of distributors and sales agents.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||